A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：ELIFE ISSN： 2050-084X 出版频率： Continuous publication 出版社： ELIFE SCIENCES PUBL LTD, SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, ENGLAND, CB3 0AX   出版社网址： http://elifesciences.org/ 期刊网址： http://elifesciences.org/ 影响因子： 8.146 主题范畴： BIOLOGY 变更情况： Newly Added by 2014 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal   Aims & scope eLife publishes outstanding research in the life sciences and biomedicine, from the most fundamental and theoretical work, through to translational, applied, and clinical research. Our 19 Senior editors and 170-member Board of Reviewing Editors are among the most respected and accomplished individuals in their fields – from human genetics and neuroscience to biophysics and epidemiology. Why publish with us? Speed Get your results out fast Initial decisions are made in a few days, post-review decisions in about a month, and most articles go through only one round of revision. Every author also has the option to make their accepted manuscript openly available shortly after receiving a final decision. Great backing We support early career scientists To support job, tenure and funding applications, the eLife Senior editor who handles your paper is willing to write a letter of recommendation that describes the significance of your article. Review process Taking the pain out of peer review The scientist editors who run eLife will give you feedback that’s constructive and fair. If invited to revise your work, you’ll receive a single consolidated list of comments, so that you know exactly what you need to do to get your work published. Research assessment eLife will not promote the Impact Factor We’ll promote your work, and provide quantitative and qualitative indicators about its reach and influence. eLife is working to expand and enrich the concept of research impact beyond the use of a single number and a journal name. Reach Get great exposure eLife papers get great media coverage in venues like the New York Times and National Geographic. We make every paper more accessible to a broad set of readers – including students, colleagues in other fields, and the public – through Impact statements, plain language summaries (eLife Digests), and selected expert commentaries (eLife Insights). eLife articles are immediately and freely available to the world – and there’s no cost to publish. Community driven Scientists make the decisions eLife is a unique, non-profit, researcher-driven initiative. Editorial decisions are made exclusively by working scientists in your field. Instructions to Authors At eLife, we’ve taken a fresh approach to peer review to save you time, and to provide clear direction and constructive input. Decisions are quick and efficient; revision requests are designed to be clear and manageable; and multiple rounds of revision are usually avoided. Here’s how it works: Initial decisions are delivered quickly Our Senior editors decide whether initial submissions are appropriate for in-depth peer review, usually in consultation with members of the Board of Reviewing Editors. Active scientists make all decisions A Senior editor assigns a member of the Board of Reviewing Editors to oversee the peer-review process. The Reviewing editor usually reviews the article him or herself, calling on one or two additional reviewers as needed. Revision requests are consolidated Reviewers get together online to discuss their recommendations, refining their feedback, and striving to provide clear and concise guidance. If the work needs essential revisions before it can be published, the Reviewing editor incorporates those requirements into a single set of instructions. Limited rounds of revision Additional rounds of revision are largely eliminated, as the Reviewing editor is able to assess most revised submissions without further outside review. Decisions and responses are available for all to read In the interests of openness and transparency we publish the most substantive parts of the decision letter after review and the associated author responses, subject to author agreement. 3 days to initial decision * 29 days to post-review decision * 90 days submission to acceptance * * median times, through the end of April 2014 Editorial Board Leadership team Randy Schekman was awarded the 2013 Nobel Prize in Physiology or Medicine, with James Rothman and Thomas Sudhof. He is Professor of Molecular and Cell Biology at the University of California, Berkeley, and an Investigator at the Howard Hughes Medical Institute. His work concerns the mechanism of membrane assembly and vesicular traffic in eukaryotic cells. He and his laboratory discovered many of the genes and proteins required for secretion in yeast and they have applied this knowledge to understand human genetic diseases that affect core components of the secretory machinery. Among other awards, he shared the Gairdner International Award, the Louisa Gross Horwitz Prize and the Lasker Award with James Rothman. A member of the American Academy of Arts and Sciences, the American Philosophical Society and the National Academy of Sciences, he was elected President of the American Society for Cell Biology in 1999 and served as Editor-in-Chief of the Proceedings of the National Academy of Sciences from 2006 to late 2011. Competing interests statement Randy Schekman has received funding from the HHMI, the UC Berkeley Miller Foundation and from the Glenn Foundation. He is the Editor-in-Chief of the Annual Reviews of Cell and Developmental Biology, Head of Faculty for Cell Biology for F1000, the Scientific Director of the Jane Coffin Childs Fund (ends 2012), and Chair of the Scientific Advisory Board of the Tamasek Life Science laboratory, Singapore (ends 2012). He was the Editor-in-Chief of the Proceedings of the National Academy of Sciences (until 2011), and was an elected Council member of the American Academy of Arts and Sciences (until this year). Fiona Watt is internationally recognised for elucidating the mechanisms that control epidermal stem cell renewal, differentiation and tissue assembly, and discovering how those processes are deregulated in disease. She obtained her DPhil from Oxford University and was a postdoc at MIT. She established her first laboratory at the Kennedy Institute in London and then moved to the Cancer Research UK (CR-UK) London Research Institute (formerly known as the Imperial Cancer Research Fund), where she worked for 20 years. From 2007 to 2012 she was the inaugural Herchel Smith Professor of Molecular Genetics at the University of Cambridge, Deputy Director of the Wellcome Trust Centre for Stem Cell Research and Deputy Director of the CR-UK Cambridge Research Institute. Since 2012 she has been Director of the Centre for Stem Cells and Regenerative Medicine at King’s College London. Fiona Watt is a member of EMBO, a fellow of the Academy of Medical Sciences and the Royal Society and an Honorary Foreign Member of the American Academy of Arts and Sciences. Competing interests statement Fiona Watt receives funding from the Wellcome Trust, the Medical Research Council, Cancer Research UK and the European Commission. She serves on the Editorial Boards of Seminars in Cell and Developmental Biology, Current Stem Cell Research and Therapy, Expert Review of Dermatology, Cell Stem Cell, StemBook, the Journal of Molecular Cell Biology, and EMBO Molecular Medicine. She is a member of the ‘Faculty of 1000’ online review service (section head, stem cells and regeneration). She is a member of the International Society for Stem Cell Research Board of Directors, a member of the Scientific Advisory Boards of the Canadian Stem Cell Network, Harvard Stem Cell Institute, Wellcome Trust Centre for Gene Regulation and Expression, North East England Stem Cell Institute, Institute for Integrated Cell-Material Sciences (iCeMS) of Kyoto University, Fondazione Piemontese per la Ricerca sul Cancro, Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Ontario-wide Stem Cell initiative and Centre for Commercialization in Regenerative Medicine, and the Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL). She is a member of the Wellcome Trust Investigator Awards, expert review group, Cell and Developmental Biology, and a member of the Steering Committee for the UK Stem Cell Bank. Detlef Weigel received his PhD in 1988 from the Max Planck Institute for Developmental Biology. After postdoctoral work at the California Institute of Technology, he joined the faculty of the Salk Institute in 1993. Since 2002, he has been director of the Department of Molecular Biology at the Max Planck Institute for Developmental Biology. His current research interests focus on natural genetic variation and evolutionary genomics of plants. Examples of recent important projects are the 1001 Genomes project for Arabidopsis thaliana, and the systematic dissection of deleterious epistasis between Arabidopsis strains due to autoimmunity. Among the awards he has received are the Young Investigator Award of the National Science Foundation, the Gottfried Wilhelm Leibniz Award of the Deutsche Forschungsgemeinschaft, and the Otto Bayer Award. He is a member of the US National Academy of Sciences, the German National Academy of Sciences Leopoldina and the Royal Society. Competing interests statement Detlef Weigel has received funding from the Max Planck Society, the Deutsche Forschungsgemeinschaft, the Foundation of the State of Baden-Württemberg, the German Ministry for Education and Research, the European Commission, the Human Frontiers Science Program Organization, and several US Federal agencies. He serves on the Editorial Boards of Annual Review of Cell and Developmental Biology and Genome Biology. He is Chair of EMBO Council, and is serving or has recently served on the Advisory Boards of the Epigenomics of Plants International Consortium, Bayer Crop Science, The Arabidopsis Information Resource, Flanders Institute of Biotechnology, Temasek Life Sciences Laboratory, and the Sainsbury Laboratory. He is a co-founder of Computomics and CeMet. Senior editors Stylianos E Antonarakis is Professor and Chairman of Genetic Medicine at the University of Geneva Medical School, and director of the iGE3 institute of Genetics and Genomics of Geneva. He is a physician-scientist, human geneticist, who extensively studied the relationship between genomic variation and phenotypic variation. He was educated in the University of Athens (MD and DSc) and the Johns Hopkins University School of Medicine (Human Genetics). His academic contributions at the Johns Hopkins and the University of Geneva spans more than 30 years, and include the understanding of the molecular bases of monogenic disorders and complex genetic disorders including the beta-thalassemias, hemophilias, trisomy 21, and the functional variability of the human genome. He has published extensively (more than 620 papers), is co-editor of the current edition of the classic textbook Genetics in Medicine, and he is listed as one of the highly cited scientists by the ISI institute (h-index 104). He was the President of the European Society of Human Genetics, and now the President of HUGO. His current interests and research projects are the functional analysis of the genome, effect of human genetic variation to phenotypic variation, the molecular pathogenesis of trisomy 21 and polygenic phenotypes, the functional characterization of the conserved fraction of the genome, diagnostics and prevention of genetic disorders, and the societal implications of genetics and genome research. Competing interests statement Stylianos Antonarakis has received funding from the Swiss National Science Foundation (SNSF), the European Union, the European Research Council (ERC), the National Institutes of Health, and the Lejeune, Gebert, and Ludwig foundations. He is the President of HUGO (the Human Genome Organization) since 2013, a member of the scientific council of the SNSF, and chair of the Genetics panel of the ERC. He is a member of the Scientific Advisory Boards of Imagine (Paris), Bioacademy Institute (Athens), and the Centre for Applied Genomics (Toronto).   Major subject area(s) Human biology and medicine Ian Baldwin studied biology and chemistry at Dartmouth College in Hanover, New Hampshire and graduated 1981 with an AB. In 1989, he received a PhD in Chemical Ecology from Cornell University, in the Section of Neurobiology and Behavior. He was an Assistant (1989), Associate (1993) and Full Professor (1996) in the Department of Biology at SUNY Buffalo. In 1996 he became the Founding Director of the Max Planck Institute for Chemical Ecology, where he now heads of the Department of Molecular Ecology. In 1999 he was appointed Honorary Professor at Friedrich Schiller University in Jena, Germany. In 2002 he founded the International Max Planck Research School at the Max Planck Institute in Jena. Baldwin's scientific work is devoted to understanding the traits that allow plants to survive in the real world. To achieve this, he has developed a molecular toolbox for the native tobacco, Nicotiana attenuata (coyote tobacco) and a graduate program that trains “genome-enabled field biologists” to combine genomic and molecular genetic tools with field work to understand the genes that matter for plant-herbivore, -pollinator, -plant, -microbial interactions under real-world conditions. He has also been driver behind the open-access publication efforts of the Max Planck Society. Competing interests statement Ian Baldwin has received funding from the Max Planck Society, the Deutsche Forschungsgemeinschaft, the US National Science Foundation, the AW Mellon Foundation, the European Research Council, and the Human Frontiers Science Program Organization. He currently serves on the editorial board of The Journal of Integrated Plant Biology; and previously, Oecologia, Ecological Studies Series, Chemoecology, and The Plant Journal. He serves on the advisory boards of the Copenhagen Plant Science Centre, Lytle Preserve, Brigham Young University, and more MPG programs than can be listed; and previously, the Institute of the Chemistry and Dynamics of the Geosphere, Jülich, the Minerva Center for Arid Ecosystems Research, Hebrew University, the Wissenschaftskolleg, Berlin, the Swiss NSF Priority Program "Plant Survival in Natural and Agricultural Ecosystems”, and the DFG Priority Programs "Biological radiations" and "Trophic interactions and dynamics of communities".   Major subject area(s) Ecology Genomics and evolutionary biology Plant biology Catherine Dulac is a Howard Hughes Medical Institute Investigator, Higgins Professor of Molecular and Cellular Biology, and Chair of the Department of Molecular and Cellular Biology in the Faculty of Arts & Sciences at Harvard University. Her work explores the molecular biology of pheromone detection and signaling in mammals, and the neural mechanisms underlying age-, species-, and sex-specific behaviors. She graduated from the Ecole Normale Supérieure, Paris; received her PhD from the University of Paris VI at the Institute of Molecular and Cellular Embryology (Nogent-sur-Marne); and was a postdoctoral fellow at Columbia University. She is a Fellow of the American Academy of Arts and Sciences; of the American Association for the Advancement of Science; and a member of the French Academy of Sciences, Institute of France. She is a recipient of the Liliane Bettencourt Prize, the Richard Lounsbery Award, the Perl/UNC Neuroscience Prize and the IPSEN Foundation Neuronal Plasticity prize. Competing interests statement Catherine Dulac receives funding from the Howard Hughes Medical Institute and the National Institutes of Health. She is a member of the editorial boards of Current Opinion in Neurobiology and The Journal of Comparative Neurology. She is a member of selection committees for the following awards and prizes: McKnight Foundation Technical Innovation Award, Radcliffe Institute for Advanced Study Fellowship Program, The Esther A. and Joseph Klingenstein Fund, the New York Stem Cell Foundation Innovator Awards in Neuroscience, the Smith Family Awards Program for Excellence in Biomedical Research and the Searle Scholars. She also serves on the Scientific Advisory Boards for the following organizations: Senomyx, Allen Institute, Friedrich Miescher Institute for Biomedical Research, and the Max Planck Institute for Medical Research. She is a member of the Visiting Committee for MIT’s Department of Brain and Cognitive Sciences, and she serves as a reviewer for the National Institutes of Health Somatosensory and Chemosensory Study Section.   Major subject area(s) Neuroscience Tony Hunter is the Renato Dulbecco Chair in Cancer Research, Director of the Salk Institute Cancer Center and an American Cancer Society Professor in the Molecular and Cell Biology Laboratory at the Salk Institute for Biological Studies in La Jolla. In 1979, through his work on tumor viruses, he discovered a new class of protein kinase that phosphorylate tyrosine. He has spent most of the last 35 years studying protein kinases and phosphatases, and the role of protein phosphorylation in cell proliferation and the cell cycle, and how aberrant protein phosphorylation can cause cancer. His group also works on other types of posttranslational modifications (PTMs), including ubiquitylation and sumoylation, and crosstalk between PTMs. He has received many awards for his work on tyrosine phosphorylation, including a Gairdner International Award, the Louisa Gross Horwitz Prize and the Wolf Prize. He is a Fellow of the Royal Society of London, a Member of the US National Academy of Sciences, the Institute of Medicine, and the American Philosophical Society. Competing interests statement Tony Hunter receives funding from the National Cancer Institute of the National Institutes of Health, and serves as Director of the Salk Institute Cancer Center funded by an NCI Cancer Center Support Grant. He is a Scientific Advisory Board member of the Sanford-Burnham Medical Research Institute Cancer Center, the Van Andel Research Institute, and the Shanghai Institute of Biochemistry and Cell Biology. He is on the editorial boards of Cell, Molecular Cell, the Proceedings of the National Academy of Sciences, EMBO Journal, and EMBO Reports.   Major subject area(s) Cell biology Prabhat Jha has been a key figure in epidemiology and economics of global health for the past decade. He is the University of Toronto Endowed Professor in Disease Control and Canada Research Chair at the Dalla Lana School of Public Health, and the founding Director of the Centre for Global Health Research at St. Michael's Hospital in Toronto. Professor Jha is a lead investigator of the Million Death Study in India, which quantifies the causes of premature mortality in over one million homes from 1997–2014 and which examines the contribution of key risk factors such as tobacco, alcohol, diet, and environmental exposures. He is co-investigator of the Disease Control Priorities Network and the author of several influential books on tobacco control, including two that helped enable a global treaty on tobacco control, now signed by over 160 countries. Prior to founding CGHR, Professor Jha served as Senior Scientist for the World Health Organization, where he co-led the work on health and poverty for the Commission on Macroeconomics and Health. Earlier, he headed the World Bank team responsible for developing the Second National HIV/AIDS Control Program in India. His advisory work has included the Government of South Africa on its national health insurance plan, and the United States Institute of Medicine on global health. Notable recognitions include the Order of Canada (2013) for contributions to global health, the  Luther Terry Award for Research on Tobacco Control (2012), The Globe and Mail 25 Transformational Canadians (2010), Top 40 Canadians under Age 40 Award (2004), the Ontario Premier’s Research Excellence Award (2004), and Gold Medal from the Poland Health Promotion Foundation (2000). Professor Jha holds an MD from the University of Manitoba and a DPhil from Oxford University, where he studied as a Canadian Rhodes Scholar. Competing interests statement Prabhat Jha has received funding from the Bill and Melinda Gates Foundation, Canadian International Development Research Agency, Canadian International Development Agency, the International Science and Technology Program of the Canadian government, and the US National Institutes of Health. He serves on the editorial board of Demography India. He advises several agencies and the Canadian government on epidemiology, disease control strategies, and tobacco control, and serves on the advisory board of the UK Biobank.   Major subject area(s) Epidemiology and global health Microbiology and infectious disease John Kuriyan is Professor of Molecular and Cell Biology and also of Chemistry at the University of California, Berkeley. Before this, he was on the faculty at The Rockefeller University, New York, where he began his career in 1987, leaving for Berkeley in 2001. Since 1990, he has been an Investigator of the Howard Hughes Medical Institute. Kuriyan completed undergraduate studies in chemistry at Juniata College, Huntingdon, PA. His doctoral research, on the dynamics of proteins, was carried out at MIT, under the guidance of Greg Petsko and Martin Karplus (Harvard University). Kuriyan’s research is aimed at understanding the structure and mechanism of the enzymes and molecular switches that carry out cellular signal transduction and DNA replication. His laboratory uses x-ray crystallography to determine the three-dimensional structures of proteins involved in signaling and replication, as well as biochemical, biophysical, and computational analyses to elucidate mechanisms. Kuriyan was elected to the U.S. National Academy of Sciences in 2001. Competing interests statement John Kuriyan has received funding from the Howard Hughes Medical Institute, the US National Institutes of Health, and the Leukemia and Lymphoma Society. He serves on the editorial board of the Proceedings of the National Academy of Sciences, and on the Scientific Advisory Boards of Carmot Therapeutics (San Francisco) and Jubilant Biosys (Bangalore). He is a founder of Nurix (San Francisco).   Major subject area(s) Biochemistry Biophysics and structural biology Richard Losick is the Maria Moors Cabot Professor of Biology, a Harvard College Professor, and a Howard Hughes Medical Institute Professor in the Faculty of Arts & Sciences at Harvard University. He received his A.B. in Chemistry at Princeton University and a Ph.D. from MIT. He was a Junior Fellow of the Harvard Society of Fellows. He is a past Chairman of the Departments of Cellular and Developmental Biology and Molecular and Cellular Biology. He is a member of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, a Member of the American Philosophical Society, a Fellow of the American Association for the Advancement of Science, and a Fellow of the American Academy of Microbiology. He is a recipient of the Camille and Henry Dreyfus Teacher-Scholar Award, the Selman A Waksman Award of the NAS, the Canada Gairdner Award, and the Louisa Gross Horwitz Prize for Biology or Biochemistry of Columbia University. Competing interests statement Richard Losick receives research funding from the National Institutes of Health. He is a member of the scientific advisory boards for the Jane Coffin Childs Fund, the KwaZulu-Natal Research Institute for Tuberculosis & HIV (K-RITH), and TenNor Therapeutics Limited. He is a member of the Board of Directors for the Foundation for Individual Rights in Education.   Major subject area(s) Microbiology and infectious disease Vivek Malhotra was a professor in the biology division at UC San Diego until 2007 and is now the ICREA Professor and Chair of the Cell and Developmental Biology at Center for Genomic Regulation (CRG) in Barcelona. His research focuses on a central station of the secretory pathway, the Golgi complex. Specifically, his work has resulted in the identification of the machinery required for the sorting and packaging of secretory cargoes. His recent work has uncovered a novel secretory routing that bypasses the conventional pathway of protein secretion. He received his BSc from Stirling University and was a Pirie–Reid scholar at Oxford; a Damon Runyon Walter Winchell and an American Cancer Society postdoctoral fellow at Stanford; and Basil O’Conner scholar, established Investigator of the American Heart Association, and Senior Investigator of Sandler’s Foundation for Asthma at UC San Diego. He received the MERCK award from the American Society of Biochemistry and Molecular Biology, is a fellow of the American association of the arts and science, and is an elected EMBO member. Competing interests statement Vivek Malhotra receives funding from ERC/European Research Council, Ministerio de Economía y Competitividad, AGAUR and the Plan Nacional (Spain) He is a Scientific Advisory Board member of TIGEM (Naples, Italy), CNR (Naples, Italy), CBMSO (Madrid, Spain) and Department of Biotechnology (India). He has served on the editorial board of Cell and was an associate editor of Molecular Biology of the Cell. He is currently on the editorial boards of Journal of Cell Biology and Current Opinion in Cell Biology.   Major subject area(s) Biochemistry Cell biology James Manley received a BS from Columbia University, a PhD from Stony Brook/Cold Spring Harbor Labs, and did postdoctoral work at MIT. He has been in the Department of Biological Sciences at Columbia University since 1980, was Chair from 1995–2001, and Julian Clarence Levi Professor of Life Sciences since 1995. His research interests center on understanding the mechanisms and regulation of gene expression in eukaryotes, especially with regard to mRNA splicing and 3’ end formation; how these processes are linked to transcription, cell signaling pathways, and maintenance of genomic stability; and how they contribute to cell differentiation and disease. He has authored or coauthored nearly 300 research articles and reviews on these topics, and is an ISI Highly Cited Researcher. Dr. Manley is a Fellow of the American Academy of Microbiology, the American Academy of Arts and Sciences, and the American Association for the Advancement of Science, and a member of the National Academy of Sciences. Competing interests statement Jim Manley receives research support from the National Institutes of Health and Columbia’s Motor Neuron Center. He is currently an Associate Editor of Gene Expression and Editor of Molecular and Cellular Biology. He is also on the editorial boards of Genes and Development, RNA, Molecular Cell, BMC Molecular Biology, BMC Biology, Recent Patents on DNA & Gene Sequences, and Transcription.   Major subject area(s) Genes and chromosomes Eve Marder is the Victor and Gwendolyn Beinfield Professor of Neuroscience at Brandeis University. Marder is a Past President of the Society for Neuroscience (SfN). Marder is a member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, and a Fellow of the Biophysical Society, the American Association for the Advancement of Science, and the International Society of Neuroethology. She received the Miriam Salpeter Award from WIN, the WF Gerard Prize from the SfN, the Miller Prize from the Society for Cognitive Neuroscience, the Karl Spenser Lashley Prize from the American Philosophical Society, and the Gruber Prize in Neuroscience. Marder served on the NIH BRAIN Initiative working group. Marder studies the dynamics of small neuronal networks, and her work was instrumental in demonstrating that neuronal circuits are not "hard-wired" but are reconfigured by neuromodulators to produce a variety of outputs. She now studies the extent to which similar network performance can arise from different sets of network parameters. Competing interests statement Eve Marder is employed by Brandeis University. She receives research and training funding from the National Institutes of Health, the Leir Foundation, and the Swartz Foundation. She serves on the Scientific Advisory Board of Janelia Farm. She is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, a Fellow of the American Association of Science, and a Fellow of the Biophysical Society. She presently serves on editorial boards of Current Biology, Current Opinion in Neurobiology, and Progress in Neurobiology.   Major subject area(s) Neuroscience Michael Marletta is the Cecil H. and Ida M. Green Professor of Chemistry and former President and CEO of The Scripps Research Institute. Previous to his appointment at Scripps, he was on the faculty of the University of California, Berkeley, the University of Michigan, and MIT. He was a HHMI Investigator while at Michigan. Marletta obtained an A.B. in chemistry and biology from the State University of New York at Fredonia, a Ph.D. from UCSF under George Kenyon and after a postdoctoral appointment at MIT under Chris Walsh, began his independent career. His work has spanned protein chemistry and enzymology. He has made many contributions to our understanding of nitric oxide signaling and more generally in molecular mechanisms of gas sensing in eukaryotes and prokaryotes. More recent studies have involved novel enzymes involved with cellulose degradation. Marletta is a member of the National Academy of Sciences, the Institute of Medicine and American Academy of Arts and Sciences. Competing interests statement Michael Marletta has received funding from the NIH, HHMI, and Burroughs-Wellcome Fund. He was a member of the PNAS Editorial Board (until July 2012) and Biochemistry. He is a Scientific Advisory Board member of Lycera, Inc., Galleon Pharmaceuticals, Viamet Pharmaceuticals, and N30. He serves on the Scientific Review Board of HHMI. He is an External Review Board member of the Vanderbilt Institute of Chemical Biology, Georgia Tech School of Chemistry and Biochemistry, and Chair, Natural Science Advisory Council, SUNY Fredonia. He is a co-founder of Omniox, Inc.   Major subject area(s) Biochemistry Sean Morrison The Morrison laboratory studies the cellular and molecular mechanisms that regulate stem cell function in the nervous and hematopoietic systems. Dr Morrison obtained his BSc in biology and chemistry from Dalhousie University (1991), then completed a PhD in immunology at Stanford University (1996), and a postdoctoral fellowship in neurobiology at Caltech (1999). From 1999 to 2011, Dr Morrison was at the University of Michigan where he Directed their Center for Stem Cell Biology. Recently, Dr Morrison moved to the University of Texas Southwestern Medical Center where he is the founding Director of the new Children’s Research Institute. Dr Morrison’s laboratory studies the mechanisms that regulate stem cell self-renewal and stem cell aging, as well as the role these mechanisms play in cancer. Dr Morrison was a Searle Scholar (2000–2003), was named in Technology Review Magazine’s list of 100 young innovators (2002), received the Presidential Early Career Award for Scientists and Engineers (2003), the International Society for Hematology and Stem Cell’s McCulloch and Till Award (2007), the American Association of Anatomists Harland Mossman Award (2008), and a MERIT Award from the National Institute on Aging. Dr Morrison has also been active in public policy issues surrounding stem cells. For example, he has twice testified before Congress and was a leader in the successful “Proposal 2” campaign to protect stem cell research in Michigan’s state constitution. Competing interests statement Sean Morrison receives funding from the Howard Hughes Medical Institute, the National Institutes of Health, and the Cancer Prevention and Research Institute of Texas. In addition to being a Senior editor for eLife, he is a member of the editorial boards of Cell Stem Cell, the Journal of Experimental Medicine, the EMBO Journal, the Faculty of 1000, Current Opinion in Cell Biology, Cancer Cell, EMBO Reports, and Stem Cell Reports. He serves on the scientific advisory boards of the California Institute for Regenerative Medicine, the University of Washington Institute for Stem Cells and Regenerative Medicine, the University of California, Los Angeles Broad Stem Cell Research Center, and the Common Fund for the National Institutes of Health Center for Regenerative Medicine. He is President-Elect of the International Society for Stem Cell Research. He is a co-founder and shareholder in OncoMed Pharmaceuticals, a consultant and shareholder in G1 Therapeutics, a shareholder in Fate Therapeutics, and a consultant for Molecular Devices.   Major subject area(s) Developmental biology and stem cells Human biology and medicine Chris PontingChris' research has had a substantial impact across diverse biomedical areas. The SMART domain database has been a major organisational principle that has proved to be of benefit across all of cellular and molecular biology; his evolutionary genomics research has provided guiding principles in differentiating genes that are similar – and those that are different – between model organisms and humans; his demonstration that approximately 8.2% of the human genome is functional demarcates the experiments necessary to fully understand transcriptional regulation; and, his evolutionary studies on non-coding RNAs provided the justification required for many that these contribute greatly to biological complexity. Chris is Deputy Director of the Medical Research Council (MRC) Functional Genomics Unit, is an Associate Faculty Member of the Wellcome Trust Sanger Institute, and is Professor of Genomics at the University of Oxford. He holds grants from the MRC, Parkinson's UK, Wellcome Trust, and the European Research Council (Advanced Grant). Competing interests statement Chris Ponting receives funding from the UK Medical Research Council, the European Research Council, Wellcome Trust, Parkinson’s UK and Systems Biology Limited. He serves on the editorial boards of Genome Biology, Human Molecular Genetics, and the Annual Review of Genomics and Human Genetics. He is Deputy Director of the MRC Functional Genomics Unit and an Associate Faculty Member of the Wellcome Trust Sanger Institute. He is an elected member of EMBO and the Academy of Medical Sciences. He serves on the Scientific Advisory Boards of ELIXIR and the Centre for Cancer Research and Cell Biology, Queen’s University.   Major subject area(s) Computational and systems biology Genomics and evolutionary biology Aviv Regev is a computational biologist who joined the Broad Institute as a core member and MIT as a faculty member in 2006. Her work investigates how complex molecular networks function and evolve in the face of genetic and environmental changes, over time-scales ranging from minutes to millions of years. Regev received her MSc from Tel Aviv University, studying biology, computer science, and mathematics in the Interdisciplinary Program for the Fostering of Excellence, where she undertook research in both theoretical and experimental biology. She received her PhD in computational biology from Tel Aviv University. Prior to joining the Broad Institute, Regev was a fellow at the Bauer Center for Genomics Research at Harvard University, where she developed new approaches to the reconstruction of regulatory networks and modules from genomic data. Regev is also an associate professor in the Department of Biology at MIT and director of the Klarman Cell Observatory at the Broad. Regev is the Director of the Cell Circuits Program at the Broad and a lead principal investigator for the Center for Cell Circuits at the Broad Institute, a Center of Excellence in Genomic Science (CEGS). Regev has been a Howard Hughes Medical Institute (HHMI) Early Career Scientist since 2009, and was named a Howard Hughes Medical Institute (HHMI) Investigator in 2013. She is a recipient of the NIH Director’s Pioneer Award, a Sloan fellowship from the Sloan Foundation, the Overton Prize from the International Society for Computational Biology, and the Earl and Thressa Stadtman Scholar Award from the American Society for Biochemistry and Molecular Biology (ASBMB). (Image Credit: Maria Nemchuk) Competing interests statement Aviv Regev receives funding from the Howard Hughes Medical Institute, the National Institutes of Health, and the Sloan Foundation. She is on the external advisory board of the San Diego Center for Systems Biology, the FAS Center for Systems Biology at Harvard, the Simons Institute for the Theory of Computing, the Jackson Laboratory, the European Molecular Biology Lab (EMBL), the SciLife Lab in Sweden, and ThermoFisher Scientific. She is on the advisory editorial board of Molecular Systems Biology and is an editorial board member of Genome Biology and Development. Regev is a consultant for Syros Phramaceuticals, GenePeeks, and CTIG (Cancer Therapeutics Innovation Group). Regev also worked for several years in the biotech industry in Israel, where she established and directed a bioinformatics research and development team at QBI, a functional genomics company.   Major subject area(s) Computational and systems biology Genomics and evolutionary biology Janet Rossant grew up in the UK and trained at the Universities of Oxford and Cambridge. She joined the Canadian Hospital for Sick Children in 2005 as Head of its Research Institute. She is also a university professor in the Department of Molecular Genetics at the University of Toronto. Throughout her career, she has been a pioneer in manipulating the mouse embryo, deriving novel stem cell lines and interrogating the mouse genome. She is a Fellow of the Royal Societies of London (2000) and Canada (1993), and a Foreign Associate of the National Academies of Science, USA (2008). She was awarded the McLaughlin Medal of the Royal Society of Canada (1998), Eli Lilly/Robert L. Noble Prize from the National Cancer Institute of Canada (2000), Killam Prize for Health Sciences (2004), and FASEB Excellence in Science Award (2004). She received the 2007 March of Dimes Prize in Developmental Biology along with the late Dr. Anne McLaren, and the 2007 Conklin Medal of the Society for Developmental Biology, of which she is a Past President. Competing interests statement Janet Rossant receives funding from the Canadian Institutes for Health Research, Ontario Research Fund, and the SickKids Foundation. She is on the editorial boards of Cell Stem Cell and Stem Cells, and she is a member of the Medical Advisory board of the Howard Hughes Medical Institute.   Major subject area(s) Developmental biology and stem cells Charles Sawyers is an Investigator of the Howard Hughes Medical Institute and the Director of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center. His studies of BCR-ABL tyrosine kinase function in chronic myeloid leukemia, in collaboration with Brian Druker and Novartis, led to the development of the kinase inhibitor imatinib as primary therapy for CML. This was followed by his discovery that BCR-ABL kinase domain mutations confer imatinib resistance, and development of the second generation Abl kinase inhibitor dasatinib, in collaboration with Bristol Myers Squibb. Sawyers' current work in prostate cancer resulted in the novel antiandrogen enzalutamide (MDV3100), discovered in collaboration with University of California, Los Angeles chemist Michael Jung, which received FDA approval in 2012. Sawyers is a member of the National Academy of Sciences and the Institute of Medicine and co-recipient of the 2009 Lasker~DeBakey Clinical Medical Research Award. Competing interests statement Charles Sawyers receives research funding from the Howard Hughes Medical Institute, the National Cancer Institute, the Starr Cancer Consortium, Stand Up to Cancer, and the Prostate Cancer Foundation. He is President Elect of the American Association of Cancer Research and will serve as President from 2013–14. He is a Councilor of the American Association of Physicians (until 2017) and serves on the editorial boards of Cell and Cancer Cell, and as a scientific advisor to Agios, Aragon, Aveo, Housey Pharmaceuticals, Merck, Nextech, Pfizer, and Tracon.   Major subject area(s) Human biology and medicine Tada Taniguchi is currently Professor of the Department of Molecular Immunology, Institute of Industrial Science of The University of Tokyo and Director of the Max Planck–The University of Tokyo Center for Integrative Inflammology. He received his Ph.D. from the University of Zurich under the supervision of Charles Weissmann. His work principally concerns the mechanisms of signal transduction and gene expression that underlie immunity and oncogenesis. Many of his research projects have stemmed from his original identification of two cytokine genes, interferon-beta and interleukin-2. These discoveries have laid the groundwork for the molecular characterization of the various systems of cytokines as well as therapeutic advances achieved by the administration of cytokines. One extension of this research was his discovery of a new family of transcription factors, the interferon regulatory factors (IRFs), which he and others have since identified as playing integral roles in the regulation of the immune system and cancer. He has received numerous awards, including the Robert Koch Prize, Pezcoller-AACR International Award for Cancer Research, and was bestowed the Person of Cultural Merit award from the Government of Japan. He was also elected Foreign Associate Member of the National Academy of Sciences, USA, in 2003. Competing interests statement Tada Taniguchi has received funding from the Ministry of Education, Culture, Sports, Science & Technology in Japan. He is a member of the editorial boards of Annual Review of Immunology, Proceedings of the National Academy of Sciences, and Immunity. He is a member of the board of directors of the Japan Molecular Biology Society, and served as member of the Science Council of Japan between 2005 and 2011. He also served as co-chairperson of the International Affairs Committee of The American Association for Cancer Research between 2002 and 2008.   Major subject area(s) Immunology Diethard Tautz is Director of the Department for Evolutionary Genetics at the Max-Planck Institute for Evolutionary Biology in Plön, Germany. He did his PhD at the EMBL in Heidelberg, followed by postdoc phases on molecular evolution in Cambridge (UK) and on the molecular analysis of developmental processes in Drosophila at the MPI for Developmental Biology in Tübingen, where he joined the group of Herbert Jäckle. Together with Herbert Jäckle, he moved to the Department of Genetics of the University of Munich in 1988 and became Professor in the Department of Zoology in Munich 1991. In 1998 he moved to a chair in "Evolutionary Genetics" at the Department of Genetics of the University of Cologne and to his present position in 2006. In his research, he combined his interests in molecular evolution and developmental biology, and was one of the founders of the emerging Evo-Devo field. His current interests center around studying the genetics of adaptations, using wild populations of the house mouse as a model system. He is also continuing his work on molecular evolution, with a special emphasis on the de novo evolution of genes. He has served as Editor-in-Chief for Development, Genes and Evolution, and was a co-founder of the open-access journal Frontiers in Zoology. Competing interests statement Diethard Tautz is funded by the Max-Planck Society and the European Research Council. He currently serves as Senior Editor for Molecular Ecology and on the editorial board of Frontiers in Zoology, Development Genes and Evolution, Trends in Genetics, and Briefings in Functional Genomics and Proteomics. He serves on a number of Max-Planck committees as well as evaluation committees of the Leibniz Society and the Universities of Basel and Heidelberg.   Major subject area(s) Genomics and evolutionary biology K VijayRaghavan Vijay’s research aims to understand motor- and olfactory- circuit assembly: from deciphering how each component is made, interacts, and stabilises into functioning in the animal to allow behaviour in the real world. Related to the development of network function is its maintenance in the mature animal; another aspect of the work in the laboratory addresses how mature neurons and muscles are maintained. The laboratory uses a genetic approach, mainly using the fruit fly but also collaborating with those using mouse and cell-culture. VijayRaghavan is Secretary to the Government of India in the Ministry of Science and Technology in the Department of Biotechnology. He temporarily holds additional charge of the Department of Biotechnology. VijayRaghavan’s research continues at the National Centre for Biological Sciences (NCBS) of the Tata Institute of Fundamental Research (TIFR) in Bangalore, India, where he is Distinguished Professor. He studied engineering at the Indian Institute of Technology, Kanpur. His doctoral work was at TIFR, Mumbai and postdoctoral work at the California Institute of Technology. VijayRaghavan is a Fellow of the Royal Society, a Foreign Associate of the US National Academy of Sciences and a Foreign Associate of the European Molecular Biology Organization. Competing interests statement K VijayRaghavan currently receives research support from the Indo–French research agency CEFIPRA, and core support from the National Centre for Biological Sciences (NCBS) of the Tata Institute of Fundamental Research (TIFR). Previous support was from the Rockefeller Foundation, the Wellcome Trust, the Indian Department of Science and Technology (DST), Department of Biotechnology (DBT), CEFIPRA, the Human Frontier Science Program (HFSP), and the US National Institutes of Health (NIH). VijayRaghavan serves on the Board of Governors of the Okinawa Institute of Science and Technology, is a member of the Advisory Committee of the Janelia Farm Research Campus of the HHMI, Chair of the Research Council of the Institute of Genomics and Integrative Biology, and Member of the Governing Council of the National Institute of Immunology. He is Associate Editor of BMC Developmental Biology, and a member of the editorial boards of Development, Seminars in Developmental Biology, and Bioconcepts. He is Chair of the Board of the Center for Cellular and Molecular Platforms (C-CAMP), a not-for-profit company of the National Centre for Biological Sciences and the stem cell institute, inStem, created to manage platform technologies and for technology transfer on the NCBS–inStem campus. He is a member of the board of the Madhuram Narayanan Centre for Exceptional Children, a not-for-profit school for disabled children in Chennai, and a member of the Board of Trustees of the Human Frontier Science Program.   Major subject area(s) Developmental biology and stem cells Genes and chromosomes Neuroscience     All reviewing editors Quarraisha Abdool Karim CAPRISA (South Africa) Karen Adelman National Institute of Environmental Health Sciences (USA) Julie Ahringer The Gurdon Institute (UK) Edoardo M Airoldi Harvard University (USA) Anna Akhmanova Utrecht University (The Netherlands) Asifa Akhtar Max Planck Institute for Immunobiology and Epigenetics (Germany) Richard Aldrich The University of Texas at Austin (USA) Richard Amasino University of Wisconsin (USA) Mohan Balasubramanian Temasek Life Sciences Laboratory (Singapore) & University of Warwick (UK) Utpal Banerjee University of California, Los Angeles (USA) Naama Barkai Weizmann Institute of Science (Israel) Marlene Bartos University of Freiburg (Germany) David Baulcombe Cambridge University (UK) Timothy Behrens Oxford University (UK) Dominique Bergmann Stanford University (USA) Carl T Bergstrom University of Washington (USA) Richard M Berry University of Oxford (UK) Douglas L Black University of California, Los Angeles (USA) Clare Blackburn MRC Centre for Regenerative Medicine, University of Edinburgh (UK) Benjamin J Blencowe University of Toronto (Canada) Jörg Bohlmann University of British Columbia (Canada) Alexander Borst Max Planck Institute of Neurobiology (Germany) Michael R Botchan University of California, Berkeley (USA) Axel Brakhage Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (Germany) Marianne E Bronner California Institute of Technology (USA) Hiram Brownell Boston College (USA) Axel T Brunger Stanford University (USA) Margaret Buckingham Institut Pasteur (France) Christopher G Burd Ronald L Calabrese Emory University (USA) Xuetao Cao Zhejiang University School of Medicine (China) Matteo Carandini University College London (UK) Arup K Chakraborty Massachusetts Institute of Technology (USA) Zhijian J Chen UT Southwestern Medical Center (USA) Joanne Chory Salk Institute for Biological Studies (USA) Jon Clardy Harvard Medical School (USA) Philip Cole Johns Hopkins University (USA) Jonathan A Cooper Fred Hutchinson Cancer Research Center (USA) Pascale Cossart Institut Pasteur (France) Giulio Cossu University College London (UK) Iain D Couzin Princeton University (USA) Ben Cravatt Scripps Research Institute (USA) Jody C Culham Western University (Canada) Michael Czech University of Massachusetts Medical School (USA) Volker Dötsch Goethe University (Germany) Valerie Daggett University of Washington (USA) Chi V Dang University of Pennsylvania (USA) Graeme W Davis University of California, San Francisco (USA) Roger Davis University of Massachusetts Medical School (USA) Bernard de Massy Institute of Human Genetics, CNRS (France) Bart De Strooper VIB and KU Leuven (Belgium) Emmanouil T Dermitzakis University of Geneva (Switzerland) Raymond J Deshaies California Institute of Technology (USA) Marcel Dicke Wageningen University (The Netherlands) Harry Dietz Johns Hopkins University (USA) Ivan Dikic Goethe University (Germany) Howard Eichenbaum Boston University (USA) Joaquin Espinosa University of Colorado (USA) Anne Ferguson-Smith Cambridge University (UK) Russ Fernald Stanford University (USA) James Ferrell Stanford University (USA) Eduardo Franco McGill University (Canada) Matthew Freeman Medical Research Council Laboratory of Molecular Biology (UK) Nir Friedman The Hebrew University of Jerusalem (Israel) Elaine Fuchs Rockefeller University (USA) Ronald N Germain National Institute of Allergy and Infectious Diseases (USA) Thomas Gingeras Cold Spring Harbor Laboratory (USA) David Ginsburg University of Michigan (USA) Christopher Glass University of California, San Diego (USA) Stephen P Goff Columbia University (USA) Todd Golub Broad Institute of MIT and Harvard (USA) Rachel Green Johns Hopkins University School of Medicine (USA) Michael R Green University of Massachusetts Medical School (USA) Peter Greenberg University of Washington (USA) Jean Greenberg University of Chicago (USA) Carol Greider Johns Hopkins University (USA) Leslie C Griffith Brandeis University (USA) Eduardo A Groisman Yale University (USA) Roderic Guigó Center for Genomic Regulation (Spain) Michael Häusser University College London (UK) Taekjip Ha Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign (USA) Bin Han National Center for Gene Research (China) Christian S Hardtke University of Lausanne (Switzerland) Maria J Harrison Boyce Thompson Institute for Plant Research (USA) Stephen C Harrison Harvard Medical School (USA) Simon I Hay Oxford University (UK) Ramanujan S Hegde Medical Research Council Laboratory of Molecular Biology (UK) Helen Hobbs UT Southwestern Medical Center (USA) Oliver Hobert Columbia University (USA) Christine E Holt University of Cambridge (UK) Gerhard Hummer The Max Planck Institute of Biophysics (Germany) Tony Hyman Max Planck Institute of Molecular Cell Biology and Genetics (Germany) Johanna Ivaska University of Turku (Finland) Elisa Izaurralde Max Planck Institute Development Biology (Germany) Reinhard Jahn Max Planck Institute for Biophysical Chemistry (Germany) Torben Heick Jensen Aarhus University (Denmark) Mark Jit London School of Hygiene & Tropical Medicine, and Public Health England (UK) Heidi Johansen-Berg University of Oxford (UK) Leemor Joshua-Tor Cold Spring Harbor Laboratory (USA) Frank Jülicher Max Planck Institute for the Physics of Complex Systems (Germany) Werner Kühlbrandt Max Planck Institute for Biophysics (Germany) James T Kadonaga University of California, San Diego (USA) Merijn R Kant University of Amsterdam (the Netherlands) Jeffery W Kelly Scripps Research Institute (USA) Philipp Khaitovich Partner Institute for Computational Biology (China) Ole Kiehn Karolinska Institute (Sweden) Eunjoon Kim Korea Advanced Institute of Science and Technology (South Korea) David Kleinfeld University of California, San Diego (USA) Daniel J Kliebenstein University of California, Davis (USA) Roberto Kolter Harvard Medical School (USA) Stephen C Kowalczykowski University of California, Davis (USA) Michael Kozlov Tel Aviv University (Israel) Robb Krumlauf Stowers Institute for Medical Research (USA) Catherine Kyobutungi Africa Population Health Research Center (Kenya) Pekka Lappalainen University of Helsinki (Finland) Michael Laub Massachusetts Institute of Technology (USA) Bruno Lemaître Ecole Polytechnique Fédérale de Lausanne (Switzerland) Beth Levine UT Southwestern Medical Center (USA) Michael Levitt Stanford University (USA) Pat Levitt University of Southern California (USA) Wenhui Li National Institute of Biological Sciences, Beijing (China) Liqun Luo Stanford University (USA) Peggy Mason University of Chicago (USA) Joan Massagué Memorial Sloan Kettering Cancer Center (USA) Diane Mathis Harvard Medical School (USA) Mark McCarthy Oxford University (UK) Sheila McCormick University of California, Berkeley & USDA Agricultural Research Service (USA) Helen McNeill The Samuel Lunenfeld Research Institute (Canada) Gil McVean Oxford University (UK) Ruslan Medzhitov Yale University (USA) Freda Miller The Hospital for Sick Children, University of Toronto (Canada) Noboru Mizushima University of Tokyo (Japan) Thorsten Nürnberger University of Tübingen (Germany) Jeremy Nathans Johns Hopkins University (USA) Richard A Neher Max Planck Institute for Developmental Biology (Germany) W James Nelson Stanford University (USA) Sacha B Nelson Brandeis University (USA) Timothy Nilsen Case Western Reserve University (USA) Magnus Nordborg Gregor Mendel Institute of Molecular Plant Biology, Austrian Academy of Sciences (Austria) Jodi Nunnari University of California, Davis (USA) Michel Nussenzweig Rockefeller University (USA) Duncan T Odom Cancer Research UK Cambridge Institute (UK) Hideyuki Okano Keio University (Japan) Richard Palmiter University of Washington (USA) Ewa Paluch University College London (UK) Duojia Pan Johns Hopkins University (USA) Dana Pe'er Columbia University (USA) Suzanne R Pfeffer Stanford University (USA) Joseph K Pickrell New York Genome Center & Columbia University (USA) Jon Pines The Gurdon Institute (UK) Kathrin Plath University of California, Los Angeles (USA) Franck Polleux Columbia University (USA) Fiona M Powrie Oxford University (UK) Carol Prives Columbia University (USA) Nick J Proudfoot Oxford University (UK) Molly Przeworski Columbia University (USA) Louis Ptáĉek University of California, San Francisco (USA) Indira M Raman Northwestern University (USA) Mani Ramaswami Trinity College, Dublin (Ireland) Satyajit Rath National Institute of Immunology (India) Danny Reinberg New York University (USA) Bing Ren University of California, San Diego School of Medicine (USA) David Ron Cambridge University (UK) Christian Rosenmund Charité (Germany) Alejandro Sánchez Alvarado Stowers Institute for Medical Research (USA) David M Sabatini Massachusetts Institute of Technology (USA) Shimon Sakaguchi Osaka University (Japan) Sjors HW Scheres Medical Research Council Laboratory of Molecular Biology (UK) Sema Sgaier Bill & Melinda Gates Foundation (USA) Feng Shao National Institute of Biological Sciences (China) Kang Shen Stanford University (USA) Ali Shilatifard Northwestern University Feinberg School of Medicine (USA) Wenying Shou Fred Hutchinson Cancer Research Center (USA) Robert H Singer Albert Einstein College of Medicine (USA) Frances K Skinner Toronto Western Research Institute, University Health Network (Canada) Nahum Sonenberg McGill University (Canada) Deepak Srivastava The Gladstone Institutes (USA) Louis Staudt National Cancer Institute (USA) Gisela Storz National Institute of Child Health and Human Development (USA) Kevin Struhl Harvard Medical School (USA) Wesley Sundquist University of Utah (USA) Sarah A Teichmann EMBL-European Bioinformatics Institute & Wellcome Trust Sanger Institute (UK) Stephen Tollman Wits University (South Africa) Peter Tontonoz University of California, Los Angeles (USA) Wilfred van der Donk University of Illinois at Urbana Champaign (USA) David C Van Essen Washington University in St Louis (USA) Gordana Vunjak-Novakovic Columbia University (USA) Amy J Wagers Harvard University (USA) David Wallach The Weizmann Institute of Science (Israel) Johannes Walter Harvard Medical School (USA) Karsten Weis ETH Zürich (Switzerland) Stephen C West London Research Institute (UK) Gary L Westbrook Vollum Institute (USA) Nicholas J White Mahidol University (Thailand) Tanya T Whitfield University of Sheffield (UK) Richard J Youle National Institute of Neurological Disorders and Stroke (USA) Stephen G Young University of California, Los Angeles (USA) Phil Zamore University of Massachusetts (USA) Xiaowei Zhuang Harvard University (USA)